The risk of chronic kidney disease (CKD) may be increased in patients living with HIV receiving tenofovir (TDF) with a ritonavir-boosted protease inhibitor compared to those who receive TDF with a non-nucleosidic reverse transcriptase inhibitor (NNRTI)
A total of 5,177 patients at high risk for renal complications were randomized and scheduled for angiography to receive intravenous sodium bicarbonate or sodium chloride and 5 days of oral acetylcysteine or placebo.
The primary endpoint of symptom resolution at day 3 was met by 54% (72/133) in the diclofenac group vs. 80% (96/120) in the norfloxacin group (risk difference 27%, 95% CI 15% to 38%, P=0.98 for non-inferiority, P<0.001 for superiority).
The researchers found that there was a change in the 16-item Quick Inventory of Depression Symptomatology-Clinician Rated of −4.1 in the sertraline group and −4.2 in the placebo group.
Uric acid-lowering therapy might improve kidney outcomes, including kidney failure events, proteinuria, and the rate of change in eGFR, and seem to reduce the risk of cardiovascular events in adults with CKD.
The renal analyses showed that compared to placebo, canagliflozin reduced the risk of kidney disease progression, including significantly reducing urinary albumin excretion and stabilizing estimated glomerular filtration rate (eGFR) over a study duration of more than six years.
Compared with individuals in the first quartile of caffeine consumption, those in the second, third, and fourth quartiles had adjusted hazard ratios for mortality of 0.88.
"Treatment with glecaprevir and pibrentasvir for 12 weeks resulted in a high rate of sustained virologic response in patients with stage 4 or 5 chronic kidney disease and HCV infection," the authors write.
Lixivaptan is a potent, selective vasopressin V2 receptor antagonist which has been found to delay the progression of an autosomal dominant form of polycystic kidney disease.
The updates include a primer on HCV resistance and guidance on treating patients who have undergone kidney transplantation.
In addition, for adult patients with CKD G3a-G5 not on dialysis, the new guideline indicates that calcitriol and vitamin D analogs should not be routinely used.
The risk for premature death increased by 62% and 42% for stage 3 CKD patients with vitamin D deficiency and elevated parathyroid hormone levels, respectively.
MPR interviewed Dr. John Stoffel to discuss the strategies for diagnosis and management of urinary retention in MS patients, as well as his recommendations for optimal care for these patients.
The researchers found in an eGFR trajectory analysis that 10.1% of participants were rapid decliners, with a mean decrease of 2.9 mL/min/1.73 m²/year.
Vabomere is a combination antibiotic that includes meropenem, a penem antibacterial, and vaborbactam, a non-suicidal beta-lactamase inhibitor.
Phase 2 trials have shown to be associated with reductions in urine protein levels following treatment with OMS721 in patients with lgA nephropathy.
The vaccine consists of the FimH bacterial adhesion protein as well as a new adjuvant designed to induce an immune response to prevent bacterial colonization of the urinary tract.
Specifically, the following presentations will no longer be available: 125mg/5mL; 100mL bottles (anticipated final date of availability: April 1, 2018), 250mg/5mL; 50mL bottles (anticipated final date of availability: January 15, 2018), 250mg/5mL; 100mL bottles (anticipated final date of availability: February 15, 2018)
"Our results highlight the opportunity to intervene both at the provider and the site level to improve testosterone prescribing," the authors write.
Based on one retrospective review of 8 years of compliance, the strongest predictors of shorter length of stay were identified as no nasogastric tube, early mobilization, early oral nutrition, early removal of epidural and urinary catheter, and nonopioid analgesia.